Navigation Links
deCODE genetics Announces Third Quarter 2007 Financial Results

e have recently completed two studies confirming the lack of undesirable drug-drug interactions, as well as a pharmacology study of its effects in the presence and absence of aspirin. The results of that study provide further evidence that DG041 inhibits platelet activation and aggregation through a crucial pathway that is not targeted by existing medications. In order to manage risk and expand our therapeutic pipeline, we are actively investigating partnership opportunities for these and earlier stage programs. Our financial results this year demonstrate our ability to create valuable assets through product development while leveraging our capabilities to generate near-term revenue streams," Dr. Stefansson concluded.

Recent highlights include:

Product Development

-- Heart attack. In its drug development program targeting the leukotriene

pathway for the prevention of heart attack, deCODE last month began

enrolling patients for its Phase IIa clinical trial for DG051, the

company's leukotriene A4 hydrolase inhibitor. In Phase I studies

completed earlier this year, DG051 significantly reduced the production

of leukotriene B4 (LTB4) in a dose dependent manner. LTB4 is a pro-

inflammatory molecule that deCODE's gene discovery and functional

biology work identified as a key factor in modulating risk of heart

attack. The Phase I studies showed DG051 to be safe and well-tolerated

at all dose levels tested, with a favourable pharmacokinetic profile.

DG051 was also recently evaluated in a 28-day Phase I study that

further demonstrated that the drug can deliver significant, sustained

reductions in LTB4 levels with once-daily dosing. The Phase IIa is a

randomized, double-blind, placebo-controlled trial that will examine

the impact of DG051 on the production of LTB4 as well as the compound's

pharmacokinetic and safety and tole

SOURCE deCODE genetics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
4. Response Genetics Reports Second Quarter 2007 Financial Results
5. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
8. Interleukin Genetics Announces Management and Board Appointments
9. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
10. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
11. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
Post Your Comments:
(Date:1/23/2015)... 23, 2015  Array BioPharma Inc. (NASDAQ: ARRY ... agreement with Novartis Pharma AG to acquire worldwide rights ... 3 development.  This agreement is conditional on the closing of ... 22, 2014, which are expected to close in the ...
(Date:1/22/2015)... 2015 Shimadzu Scientific Instruments today ... UV-visible spectrophotometer. Offering wavelength scanning from 190 to ... for applications in a variety of industries, including ... user-friendly UV-1280 enables intuitive operation, while the enhanced ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces the ... office space for Shire a leading biopharmaceutical company, at Two ... | RBJ,s Robert Richards , president, and Brian ... for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... 2015 Protocol Networks brings independent technology ... of brand-neutral, independent consultants, Protocol Networks has recently announced ... over the years, his company has attracted several clients ... Plainfield, as well as others. With the success of ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2
... the first Wisconsin governor elected to four consecutive terms, and ... governor to be tagged with radio frequency identification for digital ... Thompson, who also served as Secretary of Health and ... of the security technology firm Applied Digital's VeriChip ...
... Madison, Wis. - The Wisconsin Alumni Research Foundation ... Chemicon to commercialize research products using WARF's stem ... Tuesday. , ,Chemicon will have non-exclusive access to WARF's ... patented through the University of Wisconsin-Madison . ...
... Technologies of suburban Madison has received a Phase ... from the National Cancer Institute. The grant is to ... of protein activity, useful for cancer research. , ,Last ... grant for $2.14 million from the National Institute for ...
Cached Biology Technology:Tommy Thompson to get RFID implant 2Tommy Thompson to get RFID implant 3WARF signs stem cell agreement with California firm 2
(Date:12/11/2014)... Markets , ... addition of the "Biometrics Market in the APAC ... One major trend emerging in this market is advances ... important to upgrade biometric solutions to the latest standard ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
(Date:12/10/2014)... Baptist Medical Center today announced plans for a new medical ... $50 million capital project is part of a larger capital ... The medical education building will be located in the ... 525@vine in Wake Forest Innovation Quarter. Construction will begin immediately ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... of healthcare stakeholders address questions related to health ... disparities in a two-day invitational roundtable on March ... Health Policy, the Agency for Healthcare Research and ... Participants represent the perspectives and concerns of community ...
... Improved environmental conditions have enabled the otter ( Lutra ... years. However, the recovery of populations of this mammal has ... human activities still prevents the species from gaining a foothold. ... acts as a strong impediment to the expansion of the ...
... only a structural support protein in the microenvironment of breast ... However, laminin is far more than just a ... one of the world,s foremost breast cancer scientists have shown ... breast cancer, ,the second most common cancer and second leading ...
Cached Biology News:HIT's impact on health disparities: Will it help or harm? 2Otters on road to recovery in Andalusia 2Berkeley Lab researchers illuminate laminin's role in cancer formation 2Berkeley Lab researchers illuminate laminin's role in cancer formation 3Berkeley Lab researchers illuminate laminin's role in cancer formation 4Berkeley Lab researchers illuminate laminin's role in cancer formation 5
... the 11(R)-LOs of the sea urchin, ... hydra, H. vulgaris. The biological activity ... and tentacle regeneration, respectively, in these ... aspirin-treated recombinant COX-2 is incubated with ...
... (PEBP) does not share significant homology ... PEBP is expressed in the central ... and stomach. One important role ... inhibitory activity against several serine proteases ...
... Power Supply is designed specifically ... extensive programming capabilities including eight ... for you to set to ... intuitive PowerEase interface is faster ...
karyopherin alpha2 (2G7)...
Biology Products: